Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Peter Clark, MA, MD, FRCP: A Payer Perspective

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Opportunities to Optimize Cancer Policies Panel Discussion

Nov

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Peter Clark, MA, MD, FRCP: A Payer Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Opportunities to Optimize Cancer Policies Panel Discussion

NCCN Guidelines to Be Integrated Into OpenEvidence Medical AI Platform

Impact of Concomitant Non-Cancer Medications on Outcomes in Breast Cancer

Adding an Investigational Monoclonal Antibody to Ibrutinib May Allow Patients With CLL to Discontinue Daily Treatment

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma

Armando Giuliano Honored With 2025 William L. McGuire Memorial Lecture Award